The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

News Analysis

DOD cancer research programs face 57% funding cut in year-long continuing resolution

Pancreatic, lung, kidney cancer research programs eliminated

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The March 15 continuing resolution has gutted the Department of Defense Congressionally Directed Medical Research Program. The program’s funding was cut by 57%, compared to Fiscal Year 2024 levels—from $1.5 billion to $650 million. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior. 
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account